IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER

这项拟议的研究是一项他汀类药物的IIb期双盲安慰剂对照试验，以评估他汀类药物对80名肝硬变患者的疾病进展的影响，这些患者目前的终末期肝病模型(MELD)为≤20，没有肝细胞癌的证据。参与者应从锡达西奈医学中心(CSMC)和西北大学(NWU)的肝病诊所招募，并应包括目前正在等待或正在评估中的肝移植患者。

The proposed study is a Phase IIb, double-blinded, placebo-controlled trial of a statin to evaluate the impact of statin treatment on disease progression in 80 patients with liver cirrhosis who have a current Model for End-Stage Liver Disease (MELD) ≤ 20 and no evidence of Hepatocellular carcinoma (HCC). Participants shall be recruited from hepatology clinics at Cedar Sinai Medical Center (CSMC) and Northwestern University (NWU) and shall include patients who are currently waitlisted, or under evaluation, for a liver transplant.